{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:39:59Z","timestamp":1788176399270,"version":"build-2803163510"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose of Review<\/jats:title>\n                <jats:p>To review the current management of the axilla in breast cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent Findings<\/jats:title>\n                <jats:p>Axillary dissection is no longer indicated in patients with clinically node-negative axilla with 1\u20132 positive sentinel lymph nodes following upfront surgery or in patients with clinically node-negative axilla following neoadjuvant chemotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>Breast cancer has evolved away from routine axillary clearance to the less invasive sentinel lymph node biopsy to now complete omission of axillary sampling in select patients. We will review the most salient evidence that has shaped these practice changes over the last three decades. Current practice controversies are especially relevant for elderly populations and those receiving neoadjuvant therapy. Ongoing clinical trials will provide data to further guide breast cancer surgical management.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11912-024-01539-0","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T07:02:06Z","timestamp":1715756526000},"page":"735-743","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Axillary Management: How Much Is Too Much?"],"prefix":"10.1007","volume":"26","author":[{"given":"Nicci","family":"Owusu-Brackett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjin","family":"Facer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dionisia","family":"Quiroga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Pariser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Jhawar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget A.","family":"Oppong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,15]]},"reference":[{"key":"1539_CR1","unstructured":"American Cancer Society: Breast Cancer Facts & Figures 2022-2024, Cancer Facts & Figures 2023. Available at: https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/breast-cancer-facts-and-figures\/2022-2024-breast-cancer-fact-figures-acs.pdf and https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2023\/2023-cancer-facts-and-figures.pdf."},{"issue":"5","key":"1539_CR2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/00000658-189407000-00075","volume":"20","author":"WSI Halsted","year":"1894","unstructured":"Halsted WSI. The Results of Operations for the Cure of Cancer of the Breast Performed at the Johns Hopkins Hospital from June 1889, to January 1894. Ann Surg. 1894;20(5):497\u2013555.","journal-title":"Ann Surg"},{"issue":"1","key":"1539_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/bjc.1948.2","volume":"2","author":"DH Patey","year":"1948","unstructured":"Patey DH, Dyson WH. The prognosis of carcinoma of the breast in relation to the type of operation performed. Br J Cancer. 1948;2(1):7\u201313.","journal-title":"Br J Cancer"},{"key":"1539_CR4","doi-asserted-by":"publisher","unstructured":"AUCHINCLOSS H Jr. The nature of local recurrence following radical mastectomy. Cancer. 1958;11(3):611-9.\u00a0https:\/\/doi.org\/10.1002\/1097-0142(195805\/06)11:3<611::aid-cncr2820110323>3.0.co;2-b.\u00a0","DOI":"10.1002\/1097-0142(195805\/06)11:3<611::aid-cncr2820110323>3.0.co;2-b"},{"key":"1539_CR5","unstructured":"Cobb A, Singh P, Teshome M. Invasive Breast Cancer. The MD Anderson Surgical Oncology Manual, edited by Barry Feig, Wolters Kluwer. 2023;27\u201350."},{"issue":"8","key":"1539_CR6","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMoa020128","volume":"347","author":"B Fisher","year":"2002","unstructured":"Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347(8):567\u201375. https:\/\/doi.org\/10.1056\/NEJMoa020128.","journal-title":"N Engl J Med"},{"key":"1539_CR7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1097\/00000658-199409000-00015","volume":"220","author":"AE Giuliano","year":"1994","unstructured":"Giuliano AE, et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220:391\u20138.","journal-title":"Ann Surg"},{"key":"1539_CR8","doi-asserted-by":"publisher","unstructured":"Krag DN, Julian TB, Harlow SP, et al. NSABP-32: Phase III, randomized trial comparing axillary resection with sentinal lymph node dissection: A description of the trial.\u00a0Ann Surg Oncol.\u00a02004;11(Suppl 3):208S\u2013210S. https:\/\/doi.org\/10.1007\/BF02523630.","DOI":"10.1007\/BF02523630"},{"key":"1539_CR9","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1200\/JCO.2010.28.2491","volume":"28","author":"SR Land","year":"2010","unstructured":"Land SR, Kopec JA, Julian TB, et al. Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32. J Clin Oncol. 2010;28:3929\u201336.","journal-title":"J Clin Oncol"},{"key":"1539_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jso.21535","volume":"102","author":"T Ashikaga","year":"2010","unstructured":"Ashikaga T, Krag DN, Land SR, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol. 2010;102:111\u20138.","journal-title":"J Surg Oncol"},{"issue":"3","key":"1539_CR11","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jnma.2022.02.007","volume":"114","author":"BA Oppong","year":"2022","unstructured":"Oppong BA, Bhattacharyya O, Li Y, Obeng-Gyasi S, Sheppard VB. Receipt of breast conservation over mastectomy in Black women- does breast cancer subtype matter? J Natl Med Assoc. 2022;114(3):298\u2013307. https:\/\/doi.org\/10.1016\/j.jnma.2022.02.007.","journal-title":"J Natl Med Assoc"},{"key":"1539_CR12","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jamcollsurg.2007.02.057","volume":"205","author":"American College of Radiology","year":"2007","unstructured":"American College of Radiology. Practice guideline for the breast conservation therapy in the management of invasive breast carcinoma. J Am Coll Surg. 2007;205:362\u201376.","journal-title":"J Am Coll Surg"},{"key":"1539_CR13","doi-asserted-by":"publisher","unstructured":"Morrow M. Personalizing extent of breast cancer surgery according to molecular subtypes. Breast. 2013;22(Suppl 2):S106-9.\u00a0https:\/\/doi.org\/10.1016\/j.breast.2013.07.020.","DOI":"10.1016\/j.breast.2013.07.020"},{"issue":"11","key":"1539_CR14","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1056\/NEJM198503143121101","volume":"312","author":"B Fisher","year":"1985","unstructured":"Fisher B, Bauer M, Margolese R, Poisson R, Pilch Y, Redmond C, Fisher E, Wolmark N, Deutsch M, Montague E, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med. 1985;312(11):665\u201373.","journal-title":"N Engl J Med"},{"key":"1539_CR15","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","volume":"14","author":"T Kuehn","year":"2013","unstructured":"Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14:609\u201318.","journal-title":"Lancet Oncol"},{"key":"1539_CR16","doi-asserted-by":"crossref","unstructured":"Giuliano AE, Ballman K, McCall L, et al. Locoregional\u00a0Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial. Ann Surg. 2016;264:413\u201320.","DOI":"10.1097\/SLA.0000000000001863"},{"key":"1539_CR17","doi-asserted-by":"publisher","unstructured":"Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, Saha S, Hunt KK, Morrow M, Ballman K. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252(3):426\u201332; discussion 432\u20133. https:\/\/doi.org\/10.1097\/SLA.0b013e3181f08f32.","DOI":"10.1097\/SLA.0b013e3181f08f32"},{"key":"1539_CR18","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1200\/JCO.2016.71.0947","volume":"5","author":"GH Lyman","year":"2017","unstructured":"Lyman GH, Somerfield MR, Bosserman LD, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology Clinical practice guideline update. J Clin Oncol. 2017;5:561\u20134.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1539_CR19","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.crad.2017.11.023","volume":"73","author":"MG Wallis","year":"2018","unstructured":"Wallis MG, Kilburn-Toppin F, Taylor-Phillips S. Does preoperative axillary staging lead to overtreatment of women with screen-detected breast cancer? Clin Radiol. 2018;73(5):467\u201372. https:\/\/doi.org\/10.1016\/j.crad.2017.11.023.","journal-title":"Clin Radiol"},{"issue":"24","key":"1539_CR20","doi-asserted-by":"publisher","first-page":"00171","DOI":"10.1016\/j.amjsurg.2024.03.011","volume":"S0002\u20139610","author":"K Jiang","year":"2024","unstructured":"Jiang K, Ma C, Yang Y, McKevitt E, Pao JS, Warburton R, Dingee C, Bremang JN, Deban M, Bazzarelli A. Axillary ultrasonography for early-stage invasive breast cancer. Am J Surg. 2024;S0002\u20139610(24):00171\u20135. https:\/\/doi.org\/10.1016\/j.amjsurg.2024.03.011.","journal-title":"Am J Surg"},{"issue":"13","key":"1539_CR21","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2147\/BCTT.S273039","volume":"17","author":"MY Chen","year":"2021","unstructured":"Chen MY, Gillanders WE. Staging of the Axilla in Breast Cancer and the Evolving Role of Axillary Ultrasound. Breast Cancer (Dove Med Press). 2021;17(13):311\u201323. https:\/\/doi.org\/10.2147\/BCTT.S273039.","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"32","key":"1539_CR22","doi-asserted-by":"publisher","first-page":"3600","DOI":"10.1200\/JCO.2014.56.5838","volume":"32","author":"R Jagsi","year":"2014","unstructured":"Jagsi R, Chadha M, Moni J, Ballman K, Laurie F, Buchholz TA, Giuliano A, Haffty BG. Radiation field design in the ACOSOG Z0011 (Alliance) Trial. J Clin Oncol. 2014;32(32):3600\u20136.","journal-title":"J Clin Oncol"},{"key":"1539_CR23","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1470-2045(13)70035-4","volume":"14","author":"V Galimberti","year":"2013","unstructured":"Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23\u201301): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14:297\u2013305.","journal-title":"Lancet Oncol"},{"key":"1539_CR24","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1415340","volume":"373","author":"TJ Whelan","year":"2015","unstructured":"Whelan TJ, Olivotto IA, Parulekar WR, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015;373:307\u201316.","journal-title":"N Engl J Med"},{"key":"1539_CR25","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1415369","volume":"373","author":"PM Poortmans","year":"2015","unstructured":"Poortmans PM, Collette S, Kirkove C, et al. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med. 2015;373:317\u201327.","journal-title":"N Engl J Med"},{"key":"1539_CR26","doi-asserted-by":"publisher","unstructured":"\u2022\u2022\u00a0Poortmans PM, Weltens C, Fortpied C, Kirkove C, Peignaux-Casasnovas K, Budach V, van der Leij F, Vonk E, Weidner N, Rivera S, van Tienhoven G, Fourquet A, Noel G, Valli M, Guckenberger M, Koiter E, Racadot S, Abdah-Bortnyak R, Van Limbergen EF, Engelen A, De Brouwer P, Struikmans H, Bartelink H; European Organisation for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups. Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922\/10925): 15-year results of a randomised, phase 3 trial.\u00a0Erratum in: Lancet Oncol. 2021;22(1):e5.\u00a0Lancet Oncol. 2020;21(12):1602-1610.\u00a0https:\/\/doi.org\/10.1016\/S1470-2045(20)30472-1. (This study evaluated the addition of regional nodal irradiation to whole breast radiation therapy after BCS or mastectomy and showed reduction in regional recurrences and distant metastases.).","DOI":"10.1016\/S1470-2045(20)30472-1"},{"key":"1539_CR27","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","volume":"15","author":"M Donker","year":"2014","unstructured":"Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981\u201322023 AMAROS): a randomised, multicentre, openlabel, phase 3 non-inferiority trial. Lancet Oncol. 2014;15:1303\u201310.","journal-title":"Lancet Oncol"},{"key":"1539_CR28","doi-asserted-by":"publisher","unstructured":"Bartels SAL, Donker M, Poncet C, Sauv\u00e9 N, Straver ME, van de Velde CJH, Mansel RE, Blanken C, Orzalesi L, Klinkenbijl JHG, van der Mijle HCJ, Nieuwenhuijzen GAP, Veltkamp SC, van Dalen T, Marinelli A, Rijna H, Snoj M, Bundred NJ, Merkus JWS, Belkacemi Y, Petignat P, Schinagl DAX, Coens C, van Tienhoven G, van Duijnhoven F, Rutgers EJT. Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial. J Clin Oncol. 2023;41(12):2159-2165.\u00a0https:\/\/doi.org\/10.1200\/JCO.22.01565.","DOI":"10.1200\/JCO.22.01565"},{"issue":"36","key":"1539_CR29","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1200\/JCO.2016.69.1188","volume":"34","author":"A Recht","year":"2016","unstructured":"Recht A, Comen EA, Fine RE, Fleming GF, Hardenbergh PH, Ho AY, Hudis CA, Hwang ES, Kirshner JJ, Morrow M, Salerno KE, Sledge GW Jr, Solin LJ, Spears PA, Whelan TJ, Somerfield MR, Edge SB. Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. J Clin Oncol. 2016;34(36):4431\u201342.","journal-title":"J Clin Oncol"},{"key":"1539_CR30","doi-asserted-by":"publisher","unstructured":"Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch M, Lyons J, Matro J, Mayer IA, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Wisinski KB, Young JS, Burns JL, Kumar R. NCCN Guidelines\u00ae Insights: Breast Cancer, Version 4.2021. J Natl Compr Canc Netw. 2021;19(5):484-493.\u00a0https:\/\/doi.org\/10.6004\/jnccn.2021.0023.","DOI":"10.6004\/jnccn.2021.0023"},{"key":"1539_CR31","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/jnci\/dji021","volume":"97","author":"D Mauri","year":"2005","unstructured":"Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005;97:188\u201394.","journal-title":"J Natl Cancer Inst"},{"key":"1539_CR32","doi-asserted-by":"publisher","unstructured":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19(1):27-39.\u00a0https:\/\/doi.org\/10.1016\/S1470-2045(17)30777-5.\u00a0","DOI":"10.1016\/S1470-2045(17)30777-5"},{"key":"1539_CR33","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","volume":"26","author":"P Rastogi","year":"2008","unstructured":"Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26:778\u201385.","journal-title":"J Clin Oncol"},{"key":"1539_CR34","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","volume":"26","author":"C Liedtke","year":"2008","unstructured":"Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275\u201381.","journal-title":"J Clin Oncol"},{"key":"1539_CR35","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164\u201372.","journal-title":"Lancet"},{"key":"1539_CR36","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","volume":"30","author":"G von Minckwitz","year":"2012","unstructured":"von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30:1796\u2013804.","journal-title":"J Clin Oncol"},{"key":"1539_CR37","doi-asserted-by":"publisher","unstructured":"\u2022\u2022\u00a0Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020;382(9):810-821.\u00a0https:\/\/doi.org\/10.1056\/NEJMoa1910549.\u00a0(This trial evaluated the effect of the addition of pembrolizumab to neoadjuvant chemotherapy on the percentage of early triple-negative breast cancer patients with a pathological complete response.).","DOI":"10.1056\/NEJMoa1910549"},{"key":"1539_CR38","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","volume":"24","author":"A Schneeweiss","year":"2013","unstructured":"Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24:2278\u201384.","journal-title":"Ann Oncol"},{"key":"1539_CR39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni L, Pienkowski T, Im Y-H, et al. Efficacy and safety of neoadjuvant pertuzamab in women with locally advanced, inflammatory, or early HER2- positive breast cancer (Neosphere): a randomized multicentre, open-label, Phase 2 trial. Lancet Oncol. 2012;13:25\u201332.","journal-title":"Lancet Oncol"},{"key":"1539_CR40","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, et al. Pathological complete response and longterm clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164\u201372.","journal-title":"Lancet"},{"issue":"22","key":"1539_CR41","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB, Yanagita Y, Ohno S, Takao S, Aogi K, Iwata H, Jeong J, Kim A, Park KH, Sasano H, Ohashi Y, Toi M. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med. 2017;376(22):2147\u201359.","journal-title":"N Engl J Med"},{"key":"1539_CR42","doi-asserted-by":"publisher","unstructured":"von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, W\u00fclfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; KATHERINE Investigators. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019;380(7):617\u2013628.\u00a0https:\/\/doi.org\/10.1056\/NEJMoa1814017.","DOI":"10.1056\/NEJMoa1814017"},{"key":"1539_CR43","doi-asserted-by":"publisher","unstructured":"Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balma\u00f1a J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr; OlympiA Clinical Trial Steering Committee and Investigators. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med. 2021;384(25):2394-2405.\u00a0https:\/\/doi.org\/10.1056\/NEJMoa2105215.\u00a0","DOI":"10.1056\/NEJMoa2105215"},{"key":"1539_CR44","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","volume":"33","author":"JF Boileau","year":"2015","unstructured":"Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33:258\u201364.","journal-title":"J Clin Oncol"},{"issue":"14","key":"1539_CR45","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: The ACOSOG Z1071 (Alliance) Clinical Trial. JAMA. 2013;310(14):1455\u201361.","journal-title":"JAMA"},{"issue":"1","key":"1539_CR46","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ijrobp.2019.04.038","volume":"105","author":"BG Haffty","year":"2019","unstructured":"Haffty BG, McCall LM, Ballman KV, et al. Impact of Radiation on Locoregional Control in Women with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy and Axillary Lymph Node Dissection: Results from ACOSOG Z1071 Clinical Trial. Int J Radiat Oncol Biol Phys. 2019;105(1):174\u201382.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1539_CR47","doi-asserted-by":"publisher","unstructured":"Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, Bedrosian I, Hobbs BP, DeSnyder SM, Hwang RF, Adrada BE, Shaitelman SF, Chavez-MacGregor M, Smith BD, Candelaria RP, Babiera GV, Dogan BE, Santiago L, Hunt KK, Kuerer HM. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. J Clin Oncol. 2016;34(10):1072\u20138.\u00a0https:\/\/doi.org\/10.1200\/JCO.2015.64.0094.\u00a0","DOI":"10.1200\/JCO.2015.64.0094"},{"key":"1539_CR48","doi-asserted-by":"publisher","unstructured":"\u2022\u00a0Sharp NE, Sachs DB, Melchior NM, Albaneze P, Nardello S, Sigurdson ER, Deng M, Aggon AA, Daly JM, Bleicher RJ. Does the false-negative rate for 1 or 2 negative sentinel nodes after neo-adjuvant chemotherapy translate into a high local recurrence rate? Breast J. 2021;27(4):335-344.\u00a0https:\/\/doi.org\/10.1111\/tbj.14206. (This study demonstrated that FNR in the NSABP B-32 did not translate to local recurrence.).","DOI":"10.1111\/tbj.14206"},{"key":"1539_CR49","doi-asserted-by":"crossref","unstructured":"Mamounas EP, Bandos H, White JR, Julian TB, Khan AJ, Shaitelman SF, Torres MA, Vicini FA, Ganz PA, McCloskey SA, Paik S, Gupta N, Li XA, DiCostanzo DJ, Curran Jr WJ, Wolmark N. NRG oncology\/NSABP B-51\/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence-free interval (IBCR-FI) in patients (pts) with positive axillary (PAx) nodes who are ypN0 after neoadjuvant chemotherapy (NC) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr OT2-03-02.","DOI":"10.1158\/1538-7445.SABCS17-OT2-03-02"},{"issue":"5","key":"1539_CR50","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1097\/SLA.0000000000002313","volume":"267","author":"HM Kuerer","year":"2018","unstructured":"Kuerer HM, Rauch GM, Krishnamurthy S, et al. A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. Ann Surg. 2018;267(5):946\u201351.","journal-title":"Ann Surg"},{"issue":"12","key":"1539_CR51","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/S1470-2045(22)00613-1","volume":"23","author":"HM Kuerer","year":"2022","unstructured":"Kuerer HM, Smith BD, Krishnamurthy S, et al. Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2022;23(12):1517\u201324.","journal-title":"Lancet Oncol"},{"issue":"11","key":"1539_CR52","doi-asserted-by":"publisher","first-page":"e2026921","DOI":"10.1001\/jamanetworkopen.2020.26921","volume":"3","author":"C Cullinane","year":"2020","unstructured":"Cullinane C, Fleming C, O\u2019Leary DP, et al. Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020;3(11):e2026921.","journal-title":"JAMA Netw Open"},{"key":"1539_CR53","doi-asserted-by":"publisher","first-page":"e2200148","DOI":"10.1200\/PO.22.00148","volume":"6","author":"F Cailleux","year":"2022","unstructured":"Cailleux F, Agostinetto E, Lambertini M, et al. Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease Relapse. JCO Precis Oncol. 2022;6:e2200148.","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"1539_CR54","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.annonc.2020.11.007","volume":"32","author":"MJM Magbanua","year":"2021","unstructured":"Magbanua MJM, Swigart LB, Wu H-T, et al. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Ann Oncol. 2021;32(2):229\u201339.","journal-title":"Ann Oncol"},{"key":"1539_CR55","unstructured":"\u2022\u2022 Alliance for Clinical Trials in Oncology. A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy. clinicaltrials.gov; 2022. (This trial investigated the role of RNI in patients\u202fwith cN1 disease who have a positive SLNB following NAC and results are pending.)."},{"issue":"10","key":"1539_CR56","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1245\/s10434-018-6617-0","volume":"25","author":"SL Blair","year":"2018","unstructured":"Blair SL, Tsai C, Tafra L. ASBRS great debate: sentinel node biopsy in patients over 70 years of age. Ann Surg Oncol. 2018;25(10):2813\u20137.","journal-title":"Ann Surg Oncol"},{"key":"1539_CR57","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jgo.2016.12.003","volume":"8","author":"S Liang","year":"2017","unstructured":"Liang S, Hallet J, Simpson JS, et al. Omission of axillary staging in elderly patients with early stage breast cancer impacts regional control but not survival: A systematic review and meta-analysis. J Geriatr Oncol. 2017;8:140\u20137.","journal-title":"J Geriatr Oncol"},{"key":"1539_CR58","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1097\/SLA.0b013e31827660a8","volume":"256","author":"G Martelli","year":"2012","unstructured":"Martelli G, Boracchi P, Ardoino I, et al. Axillary dissection versus no axillary dissection in older patients with T1N0 breast cancer: 15-year results of a randomized controlled trial. Ann Surg. 2012;256:920\u20134.","journal-title":"Ann Surg"},{"key":"1539_CR59","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1200\/JCO.2005.01.5784","volume":"24","author":"CM Rudenstam","year":"2006","unstructured":"Rudenstam CM, Zahrieh D, Forbes JF, et al. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: First results of International Breast Cancer Study Group Trial 10\u201393. J Clin Oncol. 2006;24:337\u201344.","journal-title":"J Clin Oncol"},{"key":"1539_CR60","unstructured":"Choosing Wisely: Society of Surgical Oncology.\u202fhttp:\/\/www.choosingwisely.org\/clinician-lists\/sso-sentinel-node-biopsy-in-node-negative-women-70-and-over\/."},{"key":"1539_CR61","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1200\/JCO.2012.45.2615","volume":"31","author":"KS Hughes","year":"2013","unstructured":"Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: Long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31:2382\u20137.","journal-title":"J Clin Oncol"},{"key":"1539_CR62","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1245\/s10434-014-3480-5","volume":"21","author":"N Houssami","year":"2014","unstructured":"Houssami N, Macaskill P, Marinovich ML, Morrow M. The association of surgical margins and local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy: a meta-analysis. Ann Surg Oncol. 2014;21:717\u201330.","journal-title":"Ann Surg Oncol"},{"key":"1539_CR63","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1245\/s10434-018-6358-0","volume":"25","author":"IGM Poodt","year":"2018","unstructured":"Poodt IGM, Vugts G, Schipper RJ, et al. Repeat Sentinel Lymph Node Biopsy for Ipsilateral Breast Tumor Recurrence: A Systematic Review of the Results and Impact on Prognosis. Ann Surg Oncol. 2018;25:1329\u201339.","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"1539_CR64","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.1245\/s10434-017-6016-y","volume":"24","author":"M Pilewskie","year":"2017","unstructured":"Pilewskie M, Zabor EC, Mamtani A, Barrio AV, Stempel M, Morrow M. The Optimal Treatment Plan to Avoid Axillary Lymph Node Dissection in Early-Stage Breast Cancer Patients Differs by Surgical Strategy and Tumor Subtype. Ann Surg Oncol. 2017;24(12):3527\u201333. https:\/\/doi.org\/10.1245\/s10434-017-6016-y.","journal-title":"Ann Surg Oncol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-024-01539-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-024-01539-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-024-01539-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T07:52:35Z","timestamp":1720079555000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-024-01539-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,15]]},"references-count":64,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1539"],"URL":"https:\/\/doi.org\/10.1007\/s11912-024-01539-0","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,15]]},"assertion":[{"value":"29 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}